Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. - Wikidata - wikimedia - TriplyDB

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

http://www.wikidata.org/entity/Q38993068

about

The Role of Chemokines in Promoting Colorectal Cancer Invasion/Metastasis Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Therapeutic potential of chemokine signal inhibition for metastatic breast cancer The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity Adoptive cell therapy for sarcoma Immune escape mechanisms as a guide for cancer immunotherapy Live imaging and gene expression analysis in zebrafish identifies a link between neutrophils and epithelial to mesenchymal transition Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy Recent advances in understanding antitumor immunity Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma Phenotype, development, and biological function of myeloid-derived suppressor cells Genetically engineered mouse models in oncology research and cancer medicine Immunosuppression associated with chronic inflammation in the tumor microenvironment Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models Rhabdomyosarcoma: current challenges and their implications for developing therapies.Big opportunities for small molecules in immuno-oncology.Manipulation of Innate and Adaptive Immunity through Cancer Vaccines.Molecular pathways: myeloid complicity in cancer.Isolation of myeloid-derived suppressor cells subsets from spleens of orthotopic liver cancer-bearing mice by fluorescent-activated and magnetic-activated cell sorting: similarities and differences.Classification of current anticancer immunotherapies IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS.Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression.Activation of Hematopoietic Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management.Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.

P2860

Q26748194-1BE84951-01DC-4B55-B907-63A41A2E7A9B Q26749333-0B5998A3-84E8-409F-B2F9-8B481D73DBE8 Q26774312-BCB782D0-8D6C-431F-A4FB-8E6AC9505FEE Q26779184-1C2548AB-5711-4A21-A151-05CEB4620C75 Q26798116-A5C7D412-92C8-4011-8CE7-A1435D5F805D Q26829847-BD2A694E-8ED1-4BEF-81DA-A7B3AE6A4EED Q27009541-2C01FD2C-E8D3-4D28-BB62-9B0929EC33F2 Q27024502-BFED3986-AB5E-40DD-86FE-611C0999637F Q27330504-5D76E197-D66C-4063-BE6C-7AAB676937AC Q28066199-250AFF6D-F2CF-4A35-A48E-D09C9A036EEB Q28067217-6371B24C-0AE4-4D15-A250-36ADEB111CBA Q28069864-7CD5331C-59A0-44A0-8A0B-541566E03846 Q28079046-0BD3B636-4752-48B5-8AEB-1F7790A0725F Q28079323-E5E50372-5B71-48F4-9AA7-B8E6121B4F41 Q28083450-E7A92770-3D5B-43D4-98B7-68B39ACFFBC4 Q33725706-0AF9BB17-AE6E-442C-9568-82765E8A5CA3 Q34400242-7AEE9083-40AA-437C-961A-F2C209D7E2CF Q34487689-4A807A04-17FE-4C22-8E42-8441C86F92E1 Q34552791-89DC2141-482A-44ED-9E7D-3A64F182205D Q34725969-B3A77970-76E5-493C-B114-E8AA56743325 Q34732885-78654F93-1D0E-4332-A113-5C46D67D8D4F Q35149637-D2026C0D-110F-44C5-BDAA-105F0086097B Q35328929-9C704843-8E0B-46AB-81B7-B7021EBAA536 Q35663908-435816EF-89D0-4660-A1A3-E02786B64B95 Q35772377-D1456EA2-E2B6-4174-9614-583540105020 Q35958114-22115D0A-C022-4C96-ABD7-51D968D7B0BC Q36041701-D874BB0B-BDAA-4252-BFD1-240AA106C30C Q36304952-DF3D1350-0DA3-40A3-9801-7F74D827F03D Q36390700-7D601495-A5B1-4656-9884-6303231BBBB7 Q36561681-8D81666B-B929-4A36-A54B-A84F3EA138E2 Q36604012-87C71E32-B2AE-4B2C-B44F-C5CE0DA947EC Q36693101-98D379EB-7E8E-46EC-BB4A-4DAEE05EE650 Q36710927-45A20A45-BCB1-41A6-9D23-8EFE5BC4D50E Q36918248-AD205FB2-CA96-417D-9003-58CFB86B4779 Q37017190-AE9CB0F1-2A67-47E3-B090-1C7579B3B5FA Q37072889-8C7C6869-8E70-4935-85FF-FFD8D450C841 Q37134990-7733B5B0-8889-4B2E-B22A-C1931B4FF447 Q37265479-13E4E35D-2A46-42A6-BAA5-23986898101F Q37507187-F53CCAEC-7B33-4A48-B2B6-957DB801574C Q37588378-44DD2296-44AA-4468-8ADF-6E8AA60784FE

P2860

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

http://www.wikidata.org/entity/Q38993068

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

@en

type

label

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

@en

prefLabel

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

@en

P1433

Q38993068-FF52E8DE-5354-4315-ACDA-BF377AF84C76

P1476

Q38993068-3C324986-B2EF-485E-8266-2453388BB645

P2093

Q38993068-01415DB1-D665-4169-B6B6-6FAF6E78F20E

Q38993068-286D4C34-231A-4645-8CBD-A60A448EFB65

Q38993068-33BAC29B-73B3-4336-AA81-5D40CB1AB0A8

Q38993068-4E2B8FB0-13D0-45A4-9B96-251902691C6A

Q38993068-5B0B8950-A45D-41EF-AB73-D07E1CA735FC

Q38993068-D5FA988D-D378-4700-815E-CCD3D93D8377

Q38993068-DA5A55C1-A64B-47B1-81F3-F537E88D6CA3

P2860

Q38993068-0026E88A-9335-4D5D-97FB-09DE45D546FD

Q38993068-12B587F6-E9C5-45D0-8FA5-BD5CCEC4FB02

Q38993068-1529D015-0D7F-4473-B59A-2F8A9EBA969F

Q38993068-16512B48-B195-473A-AC1C-093145063A61

Q38993068-1BD99A60-D661-4032-B56C-DE287826D8CE

Q38993068-1CFDEE46-063D-4116-AA94-63F526D4D718

Q38993068-1DBA18C9-E299-43B4-96FC-9A012822F244

Q38993068-33A96B6B-598B-4B4C-A162-F257D7479E86

Q38993068-34D4CCA4-A8B2-4C7A-BD55-251A2CBD9E57

Q38993068-40689FCD-2C4B-4D1B-9336-80EFC2D8606E

P304

Q38993068-E6696EA0-1EE5-4987-919E-0D898974D775

P31

Q38993068-342B62EE-A7D3-4FAF-8312-46CB7182EA21

P356

Q38993068-E865813F-C624-4807-AB4B-0E8542F56491

P407

Q38993068-0084ED6A-BB8C-4F71-84AF-3178E6B3E6F8

P433

Q38993068-EC55043F-C05D-4F88-9B85-8F9E80C4A986

P478

Q38993068-35EC3F87-704D-4147-B07D-6ACCC394FB24

P50

Q38993068-7D5F7E6D-78D3-4005-B960-57A2828BF615

P577

Q38993068-32E2A54F-977D-4DDE-99B5-1D485B8588CF

P5875

Q38993068-7FC84EF7-06AF-4F20-997D-B3D72BF2667E

P698

Q38993068-1665D698-3B4C-464F-B7E3-4F9B41B39B1D

P932

Q38993068-208B1C32-47F4-4BED-8CCE-F206714FD6FE

P356

SCITRANSLMED.3007974

P1433

Science Translational Medicine

P1476

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy

@en

P2093

Crystal L Mackall

http://www.w3.org/2001/XMLSchema#string

Elizabeth Morse

http://www.w3.org/2001/XMLSchema#string

Hua Zhang

http://www.w3.org/2001/XMLSchema#string

Jillian P Smith

http://www.w3.org/2001/XMLSchema#string

Rosandra N Kaplan

http://www.w3.org/2001/XMLSchema#string

Steven L Highfill

http://www.w3.org/2001/XMLSchema#string

Yongzhi Cui

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

P304

237ra67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3007974

http://www.w3.org/2001/XMLSchema#string

P407

P433

237

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262532379

http://www.w3.org/2001/XMLSchema#string

P698

24848257

http://www.w3.org/2001/XMLSchema#string

P932

6980372

http://www.w3.org/2001/XMLSchema#string